November 30, 2017
According to data published by Experian MarketIQ – which tracks mergers and acquisitions activity at regional and national level – Muckle LLP is the busiest legal adviser after the first nine months of 2017.
In addition, the corporate specialists are also ranked 20th in the UK for the volume of deals completed this year, according to Experian’s latest report.
Muckle has been top of the Experian MarketIQ league at the end of 2014, 2015 and 2016 and is leading the way again this year, having worked on 22 corporate deals for clients ranging from small business startups to large companies, PLCs and private equity investors. This consistent performance has also helped the team achieve a top tier ranking for the North in Legal 500, a leading independent national legal directory.
Andrew Davison, head of the corporate team, says: “We are delighted to be named the busiest legal adviser so far in 2017. These Experian results are testament to our continued growth, having recruited two new team members in the last few months, to add to our already large team of corporate lawyers.
“We work with all sizes and types of business and have a real breadth and depth of expertise, focused on helping our clients achieve their ambitions.”
Matthew Walsh, associate in the corporate team, who collates and monitors deal activity, adds: “We have had the busiest summer we can remember. At one point the Muckle team were working on several high-value deals simultaneously: Baird Capital’s investment into CAV Ice Protection and CAV Advanced Technologies, LDC’s multi-million pound development capital investment into Patrick Parsons, the sale of O’Brien Waste Recycling Solutions to Biffa plc, Transflex Vehicle Rental’s sale to Equistone backed TOM Vehicle Rental and the takeover of Quantum Pharma Plc by Clinigen Group Plc, which valued Quantum Pharma’s share capital at £150m.”
Andrew Davison, along with partner Anthony Evans and associate Sarah Forster, led the firm’s multi-disciplinary advice to Quantum throughout that takeover, one of the region’s biggest deals this year, according to Experian.
Chris Rigg, Quantum’s CEO who had joined the Clinigen main board, says: “We are delighted with the service we have received from Muckle. They have worked closely with us to understand our objectives and have ensured that we hit every milestone throughout the deal process.
“Their technical expertise in relation to the Takeover Code and the AIM Rules has been invaluable – a real asset to the region. It was great to be able to drop in to see them whenever we wanted to and it has been a real pleasure to work with everyone in their team.”
Craig Swinhoe, who has been appointed as managing director of Quantum Pharma, adds: “We had no hesitation in deciding to appoint the team to guide us through the complex takeover process.
“Muckle’s reputation is second to none in relation to plc work and the team has worked closely with the group since 2009 on a number of strategic acquisitions. Everyone did a great job – the lawyers, their PAs, the team on reception and everyone else we bumped into were brilliant. Every time we came into Muckle’s office, they couldn’t help enough.”